Phio Pharmaceuticals
| Region | Nordamerika |
| ISIN | US71880W2044 |
| Sektor | Biotechnologie |
| Website | http://www.phiopharma.com |
Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYLTM) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. INTASYLTM therapeutics can be used as a standalone treatment or in combination with other modalities.
| Titel | Autor | Datum |
|---|---|---|
|
In Wahrheit 100 Mal so viel wert?
|
sharedeals | vor über 5 Jahren |
| Titel | Datum |
|---|---|
| MISC sinks into red for the first time in more than two years as provisions hurt | vor ungefähr 2 Monaten |
|
The Recipient Copy Deadline for 1099-B, 1099-S, and 1099-MISC is Approaching Fast: TaxBandits Makes Distribution Easy
Businesses must meet the February 18, 2025 deadline to furnish recipient copies of Forms 1099-B, ... |
vor ungefähr 3 Monaten |
| SBM Offshore finalizes asset swap with MISC Berhad | vor ungefähr 3 Monaten |
| SBM Offshore and MISC wrap up FPSO stake swap | vor ungefähr 3 Monaten |
|
SBM Offshore N.V.: SBM Offshore completes the Share Purchase Agreements with MISC Berhad
Amsterdam, January 31, 2025 SBM Offshore confirms it has completed the transactions related to t... |
vor ungefähr 3 Monaten |
| Diese Aktien könnten Dich auch interessieren | |
|---|---|
| PayPal (1 Artikel) | |
| Palatin Technologies (4 Artikel) | |
| Premier Gold Mines (1 Artikel) | |
| QIAGEN (1 Artikel) | |
| Alle anzeigen | |